Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

Alexander P. J. Vlaar, Diederik van de Beek, Janneke Horn et al.|The Lancet Rheumatology|2020

Cited by 199